News for Biogen Inc. (IDP.DE)

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia

**media[596172,596173]**

The European Commission has officially approved the marketing of Leqembi, an amyloid-beta monoclonal antibody developed by Biogen (BIIB), for use across the Eur

Organon (OGN) strategically expands its portfolio by acquiring U.S. rights for the biosimilar TOFIDENCE from Biogen (BIIB). Analysts provide a favorable

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. ( SAGE) (”œSage”) on behalf of

**media[583710]**

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) —

(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh t...

Biogen Inc (BIIB) has announced plans to establish its new global headquarters at Kendall Common in Cambridge, Massachusetts, as part of a multi-year real estat

**media[574573]**

Mizuho Financial Group analysts reveal that the spending power of America's aging population, particularly those aged 75 and above, will significantly impact the market, unlocking a $1 trillion opportunity, termed

Americans over the age of 75 are expected to grow their spending by more than $2 trillion in the next 10 years, according to Mizuho.

Biogen Inc. (NASDAQ:BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ETCompany ParticipantsPriya Singhal - Head of...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of ki

Biogen Inc. (NASDAQ:BIIB) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of North...

Shares of Biogen Inc (BIIB) surged 3.42% in mid-day trading on Mar 10. The stock reached an intraday high of $157.09, before settling at $155.53, up from it

Shares of Biogen Inc (BIIB) surged 3.32% in mid-day trading on Mar 7. The stock reached an intraday high of $154.24, before settling at $152.27, up from its

Biogen Inc. (NASDAQ:BIIB) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference Call...

Biogen Inc (BIIB) and Eisai Co., Ltd. announced on February 28, 2025, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines A